Navigation Links
Celsion Corporation Reports Year End 2012 Financial Results and Provides Business Update
Date:3/18/2013

LAWRENCEVILLE, N.J., March 18, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced financial results for the year ended December 31, 2012, and provided an update on its clinical trials of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin.  ThermoDox® is being evaluated in a Phase III clinical trial for primary liver cancer (the HEAT Study), a Phase II clinical trial for colorectal liver metastasis and a Phase II clinical trial for recurrent chest wall breast cancer.  Following review by the independent Data Monitoring Committee (DMC), on January 31, 2013, the Company announced that ThermoDox® in combination with RFA did not meet the primary endpoint of the HEAT Study in patients with hepatocellular carcinoma (HCC), also known as primary liver cancer. Based on its initial findings in the trial data, the Company will continue following the patients enrolled in the HEAT Study to the secondary endpoint, overall survival (OS).

The Company is conducting a comprehensive analysis of the data from the HEAT Study with key principal investigators, data experts and liver cancer experts.  At this time, preliminary analyses of the data indicate that ThermoDox® shows clinical activity in multiple subgroups of patients.  Development collaborations with Zhejiang Hisun Pharmaceutical Co. Ltd. (Hisun), Yakult and with multiple partners using HIFU are continuing pending further analyses of the clinical data from the HEAT Study.

"We are continuing our analysis of the HEAT Study PFS data and sub-group cohorts in an effort to determine the best course of action with ThermoDox® in HCC," said Michael H. Tardugno , Celsion's President and Chief Executive Officer.  "Our plans to foll
'/>"/>

SOURCE Celsion Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Celsion Corporation to Hold Year-End 2012 Financial Results Conference Call On Monday, March 18, 2013
2. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
3. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
4. Richard Wolf Medical Instruments Corporation: 40 Years of Innovation
5. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
6. Luminex Corporation Reports First Quarter 2012 Results
7. ShangPharma Corporation Files 2011 Annual Report on Form 20-F
8. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
9. Without Environmental Hygiene, Hand Hygiene Programs Fall Short in Reducing HAIs in Hospital Settings, Says UMF Corporation
10. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
11. DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... LONDRES, August 30, 2015 ... de l cuidado al paciente ... trayecto   Royal Philips  (NYSE: ... de IntelliSpace Cardiovascular , un sistema web de ... para acceder, analizar y compartir imágenes cardiovasculares e información ...
(Date:8/28/2015)... 2015  Delays in the launch and execution ... the decision-making process, resulting in missed opportunities and ... biopharmaceutical companies to develop a tactical approach to ... and more meaningful insights. According ... three-quarters of benchmarked study participants use review cycle ...
(Date:8/28/2015)... -- Research and Markets ( ... "Investigation Report on China,s Pranoprofen Market, 2010-2019" ... discovered by Welfide (Mitsubishi Tanabe Pharma Corporation formerly ... inflammatory drug, pranoprofen was later developed into eye ... trade name of pranopulin for the treatment of ...
Breaking Medicine Technology:Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 2Philips presenta IntelliSpace Cardiovascular en el Congreso ESC 2015 3Expediting the Pharmaceutical Market Research Process for Faster Insights 2Investigation Report on China's Pranoprofen Market, 2010-2019 2
... NEWTON, Mass., Nov. 3, 2010 Karyopharm Therapeutics Inc., a leader ... $20M Series A financing. The nuclear transport machinery plays an integral ... spectrum of human and animal disease. Karyopharm is focused on the ... i nhibitors of n uclear ...
... that a new market research report is available in its ... http://www.reportlinker.com/p0324749/Quality-for-Biologics.html Quality for Biologics – ... change control, product variation, characterisation, and regulatory concerns ... than sales of small molecule drugs, which grew by not ...
Cached Medicine Technology:Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders 2Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders 3Reportlinker Adds Quality for Biologics 2Reportlinker Adds Quality for Biologics 3Reportlinker Adds Quality for Biologics 4Reportlinker Adds Quality for Biologics 5Reportlinker Adds Quality for Biologics 6
(Date:8/31/2015)... ... August 31, 2015 , ... Dr. Paul Kovatis of Orthopedic Spine ... At OSSMC, Dr. Kovatis treats all surgical and non-surgical disorders of the leg, ankle ... entire musculoskeletal system, excluding the spine. , Dr. Paul Kovatis completed his orthopedic leg, ...
(Date:8/31/2015)... ... August 31, 2015 , ... How can healthcare ... hold down costs? , In a commentary for The American Journal of ... concept of “clinical efficacy,” which would bind parties together in agreements to intervene ...
(Date:8/31/2015)... ... August 31, 2015 , ... ... at the 16th Innovations in Healthcare(SM) Awards Event , on October 21, ... (ABL) Organization , recognizes innovative organizations and individuals who are dramatically reducing the ...
(Date:8/31/2015)... ... August 31, 2015 , ... Dad Phil, ... ribbon-cutting ceremony on Aug. 26, generously hosted by the Collinsville Chamber of Commerce, ... AdvantaClean’s National Call Center and website since Aug. 17. , The Greens have ...
(Date:8/31/2015)... ... August 31, 2015 , ... DR. LUCIANA ON ... (aka Dr. Luciana) received a total of three Silver Medal awards at ... Best (Dis)ability Film. Dr. Luciana co-wrote and co-produced this pilot with Del Weston, ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 2Health News:How “Clinical Efficacy” Can Rein in Healthcare Costs 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 2Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 3Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 4Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 5Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 6Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 7Health News:9 Finalists Named for Innovations in Healthcare(SM) ABBY Awards; Winners to be Chosen October 21 in Long Beach, CA 8Health News:Ribbon Cutting Launches AdvantaClean of Madison County 2Health News:Actor/Writer/Director/Psychology Professor Luciana Lagana Receives Three Wins at the 2015 Global Independent Film Awards for the TV Pilot Dr. Luciana on Aging and Falling 2
... , TUESDAY, Sept. 27 (HealthDay News) -- Rude employee ... from many businesses, a new U.S. study finds. ... said they,d experienced or witnessed insensitive, disrespectful or rude ... consumers said this incivility makes them less likely to ...
... rates linked to climate change will increase in several European ... study, which will be presented today (27 September 2011) at ... Belgium, France, Spain and Portugal will see the biggest climate-induced ... The research is part of the Climate-TRAP project and ...
... birth can have on the lungs of babies could be ... prematurely but may be reversed in their teenage years, according ... at the European Respiratory Society Annual Congress in Amsterdam today ... allows enough time for the infant to fully grow and ...
... Reporter , MONDAY, Sept. 26 (HealthDay News) -- U.S. health ... of blood clots in women taking newer forms of birth ... short of a definitive statement, the U.S. Food and Drug ... higher risk of blood clots in women taking the "fourth ...
... an ongoing debate: Should men over a certain age be ... treatments that may result in significant side effects if they ... by researchers at UCLA,s Jonsson Comprehensive Cancer Center has shown ... while patients with a single comorbid condition such as peripheral ...
... News) -- People with heart disease who undergo cardiac rehabilitation ... rate after exercise, a new study suggests. Researchers at ... recovery live longer than those whose hearts remain revved up ... that can do that," study author Dr. Leslie Cho, director ...
Cached Medicine News:Health News:Climate change set to increase ozone-related deaths over next 60 years 2Health News:Lung function of moderately premature babies is reduced at 8-9 years but may improve with age 2Health News:Newer Contraceptive Pills Could Raise Clot Risk, FDA Warns 2Health News:Elderly patients may be undertreated for prostate cancer 2Health News:Elderly patients may be undertreated for prostate cancer 3Health News:Cardiac Rehab May Help Heart Patients Live Longer 2
... first time, the Integrated Cytometry Solution ... post-analytical solution coupled with complete LIS ... steps a sample undergoes - and ... one - it delivers a progressive ...
Convective Air Warming Blankets...
MAMMOMAT 3000 Nova supports high-volume screening as well as interventional diagnostics. Versatile procedural capabilities include magnification, stereotactic biopsy, needle localization, and specime...
Inquire...
Medicine Products: